Kiniksa Pharmaceuticals International plc (KNSA)
KNSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/0001104659-26-019168-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KNSA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001730430 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BERMUDA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $677.6M |
| Net income | $59.0M |
| Operating income | $77.2M |
| Net margin | 8.7% |
| Operating margin | 11.4% |
| Revenue growth | +60.1% |
| Cash | $165.6M |
| Total assets | $763.6M |
| P/E (computed) | 125.5× |
| P/S (computed) | 10.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-27 |
| Cash and burn | $81.7M cash; operating cash flow $49.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 157,143,410 (2026-10-31); 151,591,518 a year earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $60.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 78,571,705 shares at the 2026-11-13 price; the latest SEC cover count is 157,143,410 as of 2026-10-31. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $286.0M | $47.3M | $47.5M | $81.7M | No debt tags | $946.0M | 10-Q 2026-10-27 |
| Q2 2026 2026-06-30 | $243.6M | $25.4M | $47.2M | $175.7M | No debt tags | $840.8M | 10-Q 2026-07-28 |
| Q1 2026 2026-03-31 | $214.3M | $22.6M | $50.2M | $190.0M | No debt tags | $754.0M | 10-Q 2026-04-28 |
| Q4 2025 2025-12-31 | $202.1M | $14.2M | $53.9M | $165.6M | No debt tags | $677.6M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $180.9M | $18.4M | $33.7M | $174.9M | No debt tags | $598.0M | 10-Q 2026-10-27 |
| Q2 2025 2025-06-30 | $156.8M | $17.8M | $28.1M | $192.0M | No debt tags | $529.3M | 10-Q 2026-07-28 |
| Q1 2025 2025-03-31 | $137.8M | $8.5M | $22.3M | $157.1M | No debt tags | $481.2M | 10-Q 2026-04-28 |
| Q4 2024 2024-12-31 | $122.5M | -$8.9M | $18.8M | $183.6M | No debt tags | $423.2M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2024-06-28 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-10-27 |
| Latest current report | 8-K | 2026-10-27 |
| Latest proxy | DEFA14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 779 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.6% |
| 1 month | +22.7% |
| 3 months | +23.8% |
| Year to date | +133.5% |
| 1 year | +139.1% |
| From 52-week high | -2.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CYTK | Cytokinetics Incorporated | $53.17 | -5.27% | $7.4B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
| RYTM | Rhythm Pharmaceuticals Inc. | $107.48 | -6.56% | $7.5B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier